EUVIMEDSkopri EUVIMED
Open access · CC BY-NC 4.0

Dose–Exposure–Response Analysis of Finerenone on Serum Potassium and Cardiovascular Outcomes Among Patients With Heart Failure: Insights From FINEARTS ‐ HF

Dosis-Expositions-Wirkungs-Analyse von Finerenon auf Serumkalium und kardiovaskuläre Ergebnisse bei Patient:innen mit Herzinsuffizienz: Erkenntnisse aus FINEARTS-HF

Thomas Eissing iD, Finnian R Mc Causland iD, Muthiah Vaduganathan iD, Sebastiaan C Goulooze iD, Eleonora Marostica, Jan Berkhout, Paul van den Berg, Nelleke Snelder iD, Dirk Garmann, Joerg Lippert iD, Meike Brinker iD, Brian L Claggett and 2 more

Diabetes, Obesity and Metabolism · 2026-11-03

DOI: 10.1111/dom.71493 ↗

Auf einen Blick

In FINEARTS-HF wurde untersucht, ob die Wirkung von Finerenon auf Kalium und kardiovaskuläre Ereignisse von Dosis/Exposition abhängt. Höhere Exposition war mit niedrigerem NT-proBNP verbunden; die Kaliumkontrolle gelang durch Dosistitration.

Fragestellung

Sind die Effekte von Finerenon auf Serumkalium und kardiovaskuläre Ereignisse bei Herzinsuffizienz dosis- bzw. expositionsabhängig?

Methode

Analyse aus FINEARTS-HF mit 6001 randomisierten Teilnehmer:innen; PK/PD- und Zeit-bis-Ereignis-Modelle zur Dosis-, Expositions- und Outcome-Beziehung.

Ergebnisse

6001 Teilnehmer:innen. Hyperkaliämie > 5,5 mmol/L: 4,3 % bei 10 mg, 2,7 % bei 20 mg, 1,5 % bei 40 mg. Höhere Exposition senkte NT-proBNP signifikant (p < 0,001); CV-Komposit nicht signifikant (p = 0,55).

Einschränkungen

FINEARTS-HF war nicht für einen randomisierten Vergleich von Dosis oder Exposition ausgelegt.

Schlussfolgerung der Autor:innen

Die Dosistitration von Finerenon war wirksam zur Kontrolle der Serumkaliumkonzentration. Das Modell spricht dafür, dass höhere erreichte Exposition mit besserer kardiovaskulärer Wirksamkeit verbunden ist.

Kernaussagen

  • Hyperkaliämie nahm bei höherer Finerenon-Dosis nicht zu.
  • Höhere Exposition war mit stärkerer NT-proBNP-Senkung verbunden.
  • Kein signifikanter Zusammenhang zur CV-Kompositendpunkt-Frequenz.

Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.

At a glance

Journal article in Diabetes, Obesity and Metabolism, published online on 2026-11-03. Written by Thomas Eissing and 13 co-authors. Institution: Bayer AG, Pharmaceuticals Research & Development, Leverkusen, Germany. 14 references. The full text is freely available (open access, CC BY-NC 4.0).

Auf einen BlickAstrattSubjectsDettalji biblijografiċiCiteRelated studies

Abstract (original language)

Background

Finerenone reduces the risk of heart failure and cardiovascular (CV) death among patients with heart failure with mildly reduced or preserved ejection fraction (HFmrEF/HFpEF). Whether the effects of finerenone to reduce CV risk are dose/exposure dependent is not clear.

Methods

In FINEARTS‐HF, 6001 participants were randomized to finerenone or placebo, where the initial and target dose of finerenone was titrated according to the baseline estimated glomerular filtration rate (eGFR; 10– > 20 mg if baseline eGFR ≤ 60; 20– > 40 mg if > 60 mL/min/1.73 m 2 ) and by serum potassium and changes in eGFR during the trial. We fitted non‐linear mixed‐effects population pharmacokinetic/pharmacodynamic and parametric repeated time‐to‐event models to explore the effect of finerenone dose on exposure ( n = 6658 plasma concentration measurements) and exposure on serum potassium ( n = 123 720 measurements), NT‐proBNP ( n = 16 971 measurements) and the primary composite outcome of total heart failure events and CV death ( n = 2366 events).

Results

The mean eGFR in those with an initial dose of 10 mg and 20 mg was 46 ± 12 and 76 ± 14 mL/min/1.73 m 2 , respectively. The frequency of hyperkalemia (> 5.5 mmol/L) was 4.3% in patients taking 10 mg finerenone, 2.7% among those taking 20 mg and 1.5% among those taking 40 mg. Simulated PK/PD data produced higher serum potassium with higher finerenone exposure in a hypothetical scenario without dose titration; however, when simulating the protocol‐guided dose titration strategy implemented in the trial, the lower observed frequency of hyperkalemia at higher finerenone exposure was explained. For the efficacy exposure–response analyses, while higher finerenone exposure was non‐significantly related to a lower frequency of CV composite events ( p = 0.55), higher exposure did result in a significantly greater reduction in NT‐proBNP concentrations ( p < 0.001).

Conclusions

Among participants of FINEARTS‐HF, finerenone dose titration was effective in managing serum potassium concentration. Although FINEARTS‐HF was not designed to test a randomized comparison of dose or exposure, the PK/PD model suggests that higher achieved exposure is associated with improved CV efficacy.

Subjects

Author keywords

cardiovascular diseaseclinical trialdose–response relationshipdrug mechanismheart failure

Authors and institutions

  • Bayer AG, Pharmaceuticals Research & Development, Leverkusen, Germany.
  • Renal Division, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, USA.
  • Cardiovascular Division, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, USA.
  • Leiden Experts on Advanced Pharmacokinetics and Pharmacodynamics (LAP&P), Leiden, the Netherlands.
  • University of Glasgow, Glasgow, Scotland, UK.

ORCID profiles: Thomas Eissing, Finnian R Mc Causland, Muthiah Vaduganathan, Sebastiaan C Goulooze, Nelleke Snelder, Joerg Lippert, Meike Brinker, John J V McMurray

Cite

APA

Eissing, T., Mc Causland, F. R., Vaduganathan, M., Goulooze, S. C., Marostica, E., Berkhout, J., van den Berg, P., Snelder, N., Garmann, D., Lippert, J., Brinker, M., Claggett, B. L., McMurray, J. J. V., & Solomon, S. D. (2026). Dose–Exposure–Response Analysis of Finerenone on Serum Potassium and Cardiovascular Outcomes Among Patients With Heart Failure: Insights From FINEARTS ‐ HF. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.71493

Vancouver

Eissing T, Mc Causland FR, Vaduganathan M, Goulooze SC, Marostica E, Berkhout J, et al. Dose–Exposure–Response Analysis of Finerenone on Serum Potassium and Cardiovascular Outcomes Among Patients With Heart Failure: Insights From FINEARTS ‐ HF. Diabetes, Obesity and Metabolism. 2026. doi:10.1111/dom.71493

BibTeX
@article{Eissing2026,
  author = {Eissing, Thomas and Mc Causland, Finnian R and Vaduganathan, Muthiah and Goulooze, Sebastiaan C and Marostica, Eleonora and Berkhout, Jan and van den Berg, Paul and Snelder, Nelleke and Garmann, Dirk and Lippert, Joerg and Brinker, Meike and Claggett, Brian L and McMurray, John J V and Solomon, Scott D},
  title = {Dose–Exposure–Response Analysis of Finerenone on Serum Potassium and Cardiovascular Outcomes Among Patients With Heart Failure: Insights From FINEARTS ‐ HF},
  journal = {Diabetes, Obesity and Metabolism},
  year = {2026},
  doi = {10.1111/dom.71493}
}
Start for free →